On October 5 Emmes announced that it entered into an agreement to acquire Panama City, Panama-based VaxTRIALS. According to data captured in the LevinPro HC database, this transaction represents the 29th contract research organization (CRO) acquisition of the year.
A specialized CRO, VaxTRIALS provides solutions in managing and monitoring vaccine clinical trial activities across Latin America. Founded in 2012, it has a presence in 11 Latin-American countries as well as the Philippines. VaxTRIALS’ local regulatory knowledge and wide network of experienced investigational sites ensures rapid trial enrollment and standards.
Founded in 1977, Emmes is a CRO with a client base that includes numerous agencies and institutes of the United States federal government and a range of biotechnology, pharmaceutical and medical device companies. Emmes was acquired by affiliates of New Mountain Capital in June 2022.
This acquisition extends Emmes’ global reach from its current base in North America, Europe and Asia to Latin America. The financial terms were not disclosed.
